Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial

The neurite outgrowth inhibitor, Nogo-A, has been shown to be overexpressed in skeletal muscle in amyotrophic lateral sclerosis (ALS); it is both a potential biomarker and therapeutic target. We performed a double-blind, two-part, dose-escalation study, in subjects with ALS, assessing safety, pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Meininger, Vincent, Pradat, Pierre-François, Corse, Andrea, Al-Sarraj, Safa, Rix Brooks, Benjamin, Caress, James B., Cudkowicz, Merit, Kolb, Stephen J., Lange, Dale, Leigh, P. Nigel, Meyer, Thomas, Milleri, Stefano, Morrison, Karen E., Orrell, Richard W., Peters, Gary, Rothstein, Jeffrey D., Shefner, Jeremy, Lavrov, Arseniy, Williams, Nicola, Overend, Phil, Price, Jeffrey, Bates, Stewart, Bullman, Jonathan, Krull, David, Berges, Alienor, Abila, Bams, Meno-Tetang, Guy, Wurthner, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026380/
https://www.ncbi.nlm.nih.gov/pubmed/24841795
http://dx.doi.org/10.1371/journal.pone.0097803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026380/
https://www.ncbi.nlm.nih.gov/pubmed/24841795
http://dx.doi.org/10.1371/journal.pone.0097803

Ejemplares similares